# Treatment of Oculopharyngeal Muscular Dystrophy With Trehalose

> **NCT04226924** · PHASE2 · WITHDRAWN · sponsor: **Bioblast Pharma Ltd.**

## Conditions studied

- Oculopharyngeal Muscular Dystrophy

## Interventions

- **DRUG:** Trehalose

## Key facts

- **NCT ID:** NCT04226924
- **Lead sponsor:** Bioblast Pharma Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-06-15
- **Primary completion:** 2018-02-15
- **Final completion:** 2018-08-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Lack of funding for company
- **Last updated:** 2020-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04226924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04226924, "Treatment of Oculopharyngeal Muscular Dystrophy With Trehalose". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04226924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*